Search results
Results from the WOW.Com Content Network
Acetazolamide, sold under the trade name Diamox among others, is a medication used to treat glaucoma, epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension (raised brain pressure of unclear cause), heart failure and to alkalinize urine.
Altitude acclimatization is the process of adjusting to decreasing oxygen levels at higher elevations, in order to avoid altitude sickness. [17] Once above approximately 3,000 metres (10,000 ft) – a pressure of 70 kilopascals (0.69 atm) – most climbers and high-altitude trekkers take the "climb-high, sleep-low" approach.
Acetazolamide is an inhibitor of carbonic anhydrase.It is used for glaucoma, epilepsy (rarely), idiopathic intracranial hypertension, and altitude sickness. For the reduction of intraocular pressure (IOP), acetazolamide inactivates carbonic anhydrase and interferes with the sodium pump, which decreases aqueous humor formation and thus lowers IOP.
This page was last edited on 12 November 2023, at 12:49 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
CMS was first described in 1925 by Carlos Monge Medrano, a Peruvian doctor who specialised in diseases of high altitude. [3] While acute mountain sickness is experienced shortly after ascent to high altitude, chronic mountain sickness may develop only after many years of living at high altitude. In medicine, high altitude is defined as over ...
High-altitude cerebral edema (HACE) is a medical condition in which the brain swells with fluid because of the physiological effects of traveling to a high altitude. It generally appears in patients who have acute mountain sickness and involves disorientation, lethargy, and nausea among other symptoms.
The second day ascends over Dead Woman's pass- the highest point on the trail at 4,200 metres. This is the most dangerous point for altitude sickness, though little time is spent at this elevation and the trail descends again to 3,600 metres. From here, the trail only descends until arriving at Machu Picchu at 2,430 metres.
Cases have also been reported between 1,500–2,500 metres or 4,900–8,200 feet in people who are at a higher risk or are more vulnerable to the effects of high altitude. Classically, HAPE occurs in persons normally living at low altitude who travel to an altitude above 2,500 meters (8,200 feet). [3]